المستودع الأكاديمي جامعة المدينة

Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar.

أعرض تسجيلة المادة بشكل مبسط

dc.contributor Epicentre, Paris, France.
dc.creator Guthmann, J P
dc.creator Pittet, A
dc.creator Lesage, A
dc.creator Imwong, M
dc.creator Lindegardh, N
dc.creator Min Lwin, M
dc.creator Zaw, T
dc.creator Annerberg, A
dc.creator de Radiguès, X
dc.creator Nosten, F
dc.date 2008-01
dc.date.accessioned 2017-01-31T07:10:49Z
dc.date.available 2017-01-31T07:10:49Z
dc.identifier Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. 2008, 13 (1):91-8 Trop. Med. Int. Health
dc.identifier 1365-3156
dc.identifier 18291007
dc.identifier 10.1111/j.1365-3156.2007.01978.x
dc.identifier http://hdl.handle.net/10144/26152
dc.identifier http://fieldresearch.msf.org/msf/handle/10144/26152
dc.identifier Tropical Medicine & International Health
dc.identifier.uri http://dspace.mediu.edu.my:8181/xmlui/handle/10144/26152
dc.description OBJECTIVE: To assess the efficacy of chloroquine in the treatment of Plasmodium vivax malaria in in Dawei District, southern Myanmar. METHODS: Enrolled patients at Sonsinphya clinic >6 months of age were assessed clinically and parasitologically every week for 28 days. To differentiate new infections from recrudescence, we genotyped pre- and post-treatment parasitaemia. Blood chloroquine was measured to confirm resistant strains. RESULTS: Between December 2002 and April 2003, 2661 patients were screened, of whom 252 were included and 235 analysed. Thirty-four per cent (95% CI: 28.1-40.6) of patients had recurrent parasitaemia and were considered treatment failures. 59.4% of these recurrences were with a different parasite strain. Two (0.8%) patients with recurrences on day 14 had chloroquine concentrations above the threshold of 100 ng/ml and were considered infected with chloroquine resistant parasites. 21% of failures occurred during the first 3 weeks of follow-up: early recurrence and median levels of blood chloroquine comparable to those of controls suggested P. vivax resistance. CONCLUSIONS: Plasmodium vivax resistance to chloroquine seems to be emerging in Dawei, near the Thai-Burmese border. While chloroquine remains the first-line drug for P. vivax infections in this area of Myanmar, regular monitoring is needed to detect further development of parasite resistance.
dc.language en
dc.publisher Wiley-Blackwell
dc.rights Archived on this site with the kind permission of Wiley-Blackwell, [url]http://www.blackwell-synergy.com/loi/tmi[/url]
dc.title Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar.


الملفات في هذه المادة

الملفات الحجم الصيغة عرض

لا توجد أي ملفات مرتبطة بهذه المادة.

هذه المادة تبدو في المجموعات التالية:

أعرض تسجيلة المادة بشكل مبسط